28 completed, 2 recruiting, 1 terminated, 1 withdrawn. 32 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 32 | Completed 28, Recruiting 2, Terminated 1, Withdrawn 1 |
| Phase 2 | 5 | Completed 4, Terminated 1 |
Follow Vaccinia: new trials by email Literature Review of Vaccinia trials Research Report on Vaccinia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| IDOV-Immune for Advanced Solid Tumors IDOV-Immune (oncolytic vaccinia virus) - Colorectal Cancer, Pancreatic Cancer | Phase 1 | Recruiting | ViroMissile, Inc. | 78 | 2025-08-25 | 2026-08-05 |
| Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors vvDD-hIL-2-RG-1 - Gastric Neoplasms, Esophageal Cancer | Phase 1 | Recruiting | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | 18 | 2025-05-06 | 2025-06-03 |
| Open Multi-cohort Study of the First Phase of Safety of a Drug Based on Double Recombinant Vaccinia Virus VV-GMCSF-Lact Double Recombinant Vaccinia Virus VV-GMCSF-Lact - Oncolytic Virotherapy | Phase 1 | Completed | "Oncostar" LLC | 34 | 2022-05-11 | 2026-04-21 |
| A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors BT-001, Pembrolizumab [KEYTRUDA®] - Metastatic Cancer, Soft Tissue Sarcoma | Phase 1 / Phase 2 | Terminated | Transgene | 31 | 2021-02-25 | 2025-11-21 |
| A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors ASP9801, Pembrolizumab - Metastatic Cancer, Solid Tumors | Phase 1 | Completed | Astellas Pharma Global Development, Inc. | 72 | 2019-09-03 | 2025-04-22 |
| Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer Olvi-Vec, Platinum-doublet with or without bevacizumab - Ovarian Cancer, Peritoneal Carcinomatosis | Phase 1 / Phase 2 | Completed | Genelux Corporation | 46 | 2016-05-01 | 2026-06-12 |
| Safety Study of Attenuated Vaccinia Virus (GL-ONC1)With Combination Therapy in Head & Neck Cancer GL-ONC1 - Cancer of Head and Neck | Phase 1 | Completed | Genelux Corporation | 19 | 2012-04-01 | 2015-08-25 |
| A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis GL-ONC1 - Peritoneal Carcinomatosis | Phase 1 / Phase 2 | Completed | Genelux GmbH | 9 | 2012-02-01 | 2025-04-30 |
| Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma JX-594, Irinotecan - Colorectal Carcinoma, CRC | Phase 1 / Phase 2 | Completed | Jennerex Biotherapeutics | 52 | 2012-01-01 | 2026-08-05 |
| Phase 1b Dose Escalation Study of Intravenous JX-594 in Metastatic, Refractory Colorectal Carcinoma Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594) - Carcinoma, Colorectal | Phase 1 | Completed | Jennerex Biotherapeutics | 15 | 2010-09-08 | 2026-07-08 |
| Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594) - Neuroblastoma, Rhabdomyosarcoma | Phase 1 | Completed | Jennerex Biotherapeutics | 6 | 2010-08-01 | 2016-01-21 |
| Safety Study of GL-ONC1, an Oncolytic Virus, in Patients With Advanced Solid Tumors GL-ONC1 - Advanced Cancers (Solid Tumors) | Phase 1 | Completed | Genelux GmbH | 43 | 2008-11-01 | 2025-04-24 |
| Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594) - Melanoma, Lung Cancer | Phase 1 | Completed | Jennerex Biotherapeutics | 23 | 2008-06-01 | 2015-12-03 |
| Safety Study of Modified Vaccinia Virus to Cancer Vaccinia virus (vvDD-CDSR) - Melanoma, Breast Cancer | Phase 1 | Completed | David Bartlett | 26 | 2008-05-01 | 2015-12-28 |
| SIGA-246 to Treat Smallpox Vaccine: SIGA-246 - Vaccinia | Phase 1 | Withdrawn | National Institute of Allergy and Infectious Diseases (NIAID) | 2006-03-13 | 2017-07-02 | |
| A Study of Recombinant Vaccinia Virus to Evaluate the Safety and Efficacy of a Transdermal Injection Within the Tumor of Patients With Primary or Metastatic Hepatic Carcinoma JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF) - Neoplasms, Liver | Phase 1 | Completed | Jennerex Biotherapeutics | 14 | 2006-01-01 | 2026-05-19 |
| Active Specific Intranodal Immunotherapy of Recombinant Vaccinia Virus in Locally Advanced to Metastatic Melanoma Intranodal immunization with a recombinant vaccinia virus expressing 5 transgenes, Intranodal booster immunizations with synthetic melanoma associated epitopes - Melanoma | Phase 1 / Phase 2 | Completed | University Hospital, Basel, Switzerland | 15 | 2002-11-01 | 2009-12-02 |
| Study of Reactogenicity, Safety, Immunogenicity, and Pock Lesion Formation of a Cell-Cultured Smallpox Vaccine Compared to Dryvax® Cell-Cultured Smallpox Vaccine compared to Dryvax® - Smallpox | Phase 1 | Completed | DynPort Vaccine Company LLC, A GDIT Company | 350 | 2002-03-01 | 2011-06-30 |
| A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Immuno-AG Recombinant HIV gp160 in Asymptomatic HIV Seropositive Individuals gp160 Vaccine (Immuno-AG), Hepatitis B Vaccine (Recombinant) - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 55 | 2021-11-02 | |
| Phase I Safety and Immunogenicity Trial of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (gp160; VaxSyn) HIVAC-1e, gp160 Vaccine (MicroGeneSys) - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 35 | 2021-10-27 |
Showing 20 of 32. Sign in to see all of them.
HIV Infections (14) · Neoplasms (6) · Melanoma (5) · Colorectal Neoplasms (4) · Acquired Immunodeficiency Syndrome (3) · Breast Neoplasms (3) · Liver Neoplasms (3) · Neoplasm Metastasis (3) · Carcinoma, Hepatocellular (2) · Carcinoma, Renal Cell (2) · Colonic Neoplasms (2) · Esophageal Neoplasms (2) · Head and Neck Neoplasms (2) · Lung Neoplasms (2)
DNA Virus Infections (32) · Infections (32) · Poxviridae Infections (31) · Virus Diseases (30) · Urogenital Diseases (18) · Genital Diseases (16) · Immune System Diseases (15) · Blood-Borne Infections (14) · Communicable Diseases (14) · Immunologic Deficiency Syndromes (14) · Lentivirus Infections (14) · Neoplasms by Site (14) · RNA Virus Infections (14) · Retroviridae Infections (14) · Sexually Transmitted Diseases (14)
VaxSyn HIV-1 (gp160) vaccine (8) · HIVAC-1e (6) · Hepatitis B Vaccines (2) · Smallpox Vaccine (2) · pembrolizumab (2) · Bevacizumab (1) · Granulocyte-Macrophage Colony-Stimulating Factor (1) · Irinotecan (1)
National Institute of Allergy and Infectious Diseases (NIAID) (14) · Jennerex Biotherapeutics (5) · Genelux Corporation (2) · Genelux GmbH (2) · "Oncostar" LLC (1) · Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) (1) · Astellas Pharma Global Development, Inc. (1) · Bristol-Myers Squibb (1) · David Bartlett (1) · DynPort Vaccine Company LLC, A GDIT Company (1) · Transgene (1) · University Hospital, Basel, Switzerland (1) · ViroMissile, Inc. (1)
United States (25) · Canada (2) · France (2) · South Korea (2) · Australia (1) · Belgium (1) · Germany (1) · Russia (1) · Switzerland (1) · United Kingdom (1)
Belshe R (5) · Clements ML (3) · Couch R (3) · Dolin R (3) · Levine M (3) · Wright P (3) · Corey L (2) · David Kirn, MD (2) · Koff W (2) · Daniel Oertli, M.D. (1) · Derek Jonker, MD (1) · Giulio C Spagnoli, M.D. (1) · Gorse G (1) · Hardev Pandha, MD,FRCP,FRACP,PhD (1)
PMID 11874634, PMID 14577912, PMID 18495536, PMID 19935776, PMID 29773661, PMID 37227734, PMID 42383154